What records are connected here?
- Evidence lanes
- 3
- Source years
- 17
- Drugs@FDA applications
- 14
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Limited human dataHeart and blood vessels
Vasopressin is a peptide hormone that narrows blood vessels and helps the kidneys hold on to water. Vasostrict is a synthetic version of arginine vasopressin.1 FDA approved Vasostrict in 2014 to raise blood pressure in adults with vasodilatory shock whose blood pressure stays low despite fluids and catecholamine drugs.1,2 The label’s summary of its human evidence is brief: blood pressure rose in seven studies in septic shock and eight after heart surgery, with no further detail on study design.1
| What it is | A synthetic polypeptide hormone, arginine vasopressin, that acts on V1 receptors in blood vessels and V2 receptors in the kidney, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Vasostrict with an original approval date of April 17, 2014. The cited label has no boxed warning.1,2 |
| Human evidence | Studies in septic shock and in shock after heart surgery, summarized in one sentence in the label without sample sizes or design details.1 |
| Evidence strength | Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned |
Vasopressin is a polypeptide hormone. Vasostrict is a sterile solution of synthetic arginine vasopressin, according to the label.1
In the United States, Drugs@FDA lists it as Vasostrict, approved under NDA 204485.2
The label states that vasopressin narrows blood vessels by binding V1 receptors on vascular smooth muscle, and causes the kidneys to retain water by stimulating V2 receptors.1
The label states that increases in systolic and mean blood pressure were observed in seven studies in septic shock and eight in vasodilatory shock after heart surgery.1
The label does not report the size or design of these studies, or effects on survival.1
Evidence-strength label: Limited human data. How this label is assigned
Yes. Drugs@FDA lists Vasostrict, application NDA 204485, with an original approval date of April 17, 2014.2
The Vasostrict label cited here (DailyMed SPL version 49, published May 18, 2026) states that it is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.1
The label has no boxed warning. Its warnings state that it can worsen heart function and that reversible diabetes insipidus can follow when treatment stops.1
Whether raising blood pressure with it improves survival: the label’s clinical studies section reports blood pressure effects only.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Vasopressin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Vasopressin are a bounded selection, not every registration or paper about Vasopressin. For the years before Vasopressin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Vasopressin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Vasopressin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Vasostrict for vasodilatory shock. The label summarizes studies in septic shock and after heart surgery in which blood pressure rose, without reporting their size or design.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Vasostrict for vasodilatory shock. The label summarizes studies in septic shock and after heart surgery in which blood pressure rose, without reporting their size or design.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 5, 2026
Oxytocin, vasopressin, and their crosstalk in sexually-dimorphic psychiatric conditions.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Oxytocin, vasopressin, and their crosstalk in sexually-dimorphic psychiatric conditions.↗Source date November 5, 2026Literature metadata · added November 15, 2026
International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance).↗Source date November 1, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT05958342↗Source date October 30, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
30 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00269685 at 2026-11-15T22:08:31.832Z. Its registry update date was 2006-05-29, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00358579 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-03-17, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00379522 at 2026-11-15T22:08:31.832Z. Its registry update date was 2014-11-05, and PeptideScanner's reviewed identity mapping was vasopressin.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span September 25, 1998 to November 5, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 41862144 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39438674 in Nature reviews. Nephrology as Journal Article, Review, Consensus Statement, with publication-date metadata of 2024-10-22 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05958342 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04501861 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07633600 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Literature metadata
PubMed lists PMID 40602377 in Hormone research in paediatrics as Journal Article, Review, with publication-date metadata of 2025-07-02 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40867749 in Animals : an open access journal from MDPI as Journal Article, Review, with publication-date metadata of 2025-08-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42677919 in Endocrine-related cancer as Journal Article, Review, with publication-date metadata of 2026-09-01 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42647984 in Current opinion in pharmacology as Journal Article, Review, with publication-date metadata of 2026-08-10 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06709573 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was vasopressin.↗
Literature metadata
PubMed lists PMID 41667271 in Archives of disease in childhood as Journal Article, Review, Case Reports, with publication-date metadata of 2026-08-19 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42653310 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-08-16 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026